Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

Meletios A Dimopoulos; A. Keith Stewart; Tamás Masszi; Ivan Špıčka; Albert Oriol; Roman Hájek; Laura Rosiñol; David S. Siegel; Georgi Mihaylov; Vesselina Goranova‐Marinova; Péter Rajnics; Aleksandr Suvorov; Rubén Niesvizky; Andrzej Jakubowiak; Jesús F. San Miguel; Heinz Ludwig; Antonio Palumbo; Mihaela Obreja; Sanjay Aggarwal; Philippe Moreau

doi:10.1111/bjh.14549

Related publications

Article2014

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Vesselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Michael Wang, Vladimír Maisnar, Jiří Minařík, William Bensinger, María-Victoria Mateos, Dina Ben‐Yehuda, Vishal Kukreti, Naseem J. Zojwalla, Margaret Tonda, Xinqun Yang, Biao Xing, Philippe Moreau, Antonio Palumbo

Article2017

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

Meletios A Dimopoulos, A. Keith Stewart, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Veselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Sunhee Ro, Sanjay Aggarwal, Philippe Moreau, Antonio Palumbo

Article2023

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Thomas G. Martin, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau

Article2021

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos

Article2011

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

Philippe Moreau, Antonio Palumbo, A. Keith Stewart, S. Vincent Rajkumar, Andrzej Jakubowiak, Kathleen G. Halka, Vesselina Goranova‐Marinova, Horia Bumbea, Kelly Pendergrass, Anca Roxana Lupu, Meletios A Dimopoulos, Albert Oriol Rocafiguera, J. G. Gandhi, Georgi Mihaylov, Tamás Masszi, J. Matous, Gustavo Fonseca, Richard Bryce, David S. Siegel